NCT05994300Active, not recruiting
Moderately Hypofractionated Adaptive Radiotherapy for Cervical Cancer
Clinical Research of Moderately Hypofractionated Radiotherapy for Cervical Cancer
Source: ClinicalTrials.gov · Last updated 8 Jun 2025
Brief summary (registry, in English)
External radiation given in 25 fractions or so together with weekly chemotherapy and followed by 5 or 6 fractions of brachytherapy is the standard of care for patients with locally advanced cervical cancer. We hope to develop external moderately hypofractionated radiotherapy of cervical cancer based on adaptive radiotherapy.The objective of this study is to evaluate the efficacy and treatment-related toxicity of moderately hypofractionated adaptive radiotherapy in the treatment of cervical cancer.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 5 Aug 2023
- Start date
- 19 Sept 2023
- Primary completion date
- 22 Jul 2024
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Cervical cancer
- NCT number
- NCT05994300
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 19 Sept 2023 to the primary completion date, 22 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who had chemotherapeutic, surgical and/or radiotherapy treatment
- Previous pelvic or abdominal radiotherapy
- Other factors that contraindicate experimental therapy
Other
- FIGO stage IIIA, IIIB, IIIC2, IVA or IVB
- FIGO stage IIIC1 with node greater than 1.5 cm, common iliac node or greater than 2 pathological nodes
- Patient unable to undergo MR scan
- ECOG performance status greater than 2
- Not a cisplatin candidate
Who the study is looking for
- Age 18 years to 70 years
- FIGO Stage IB1, IB2, IB3, IIA or IIB cervical cancers
- FIGO stage IIIC1 cervical cancers are candidates but must meet all the following criteria:largest node is less than 1.5 cm,less than 3 pathological nodes,No nodes located in the common iliac chain
- Histology: squamous
- Candidate for definitive chemoradiotherapy to be delivered with weekly cisplatin
- Brachytherapy candidate
- Functional State Eastern Cooperative Oncology Group (ECOG)0-2
Age in the registry: 18 years to 70 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.